Cantor Fitzgerald Maintains Overweight on Rigel Pharmaceuticals, Lowers Price Target to $5

Cantor Fitzgerald maintains Rigel Pharmaceuticals (NASDAQ:RIGL) with a Overweight and lowers the price target from $7 to $5.